- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Indivior PLC Chart
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenIndivior PLC Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Indivior PLC
Webinar zu Indivior PLC
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)7,330-23,220
- Jahrestief / Hoch ($)7,330-23,220
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Indivior PLC
Termine von Indivior PLC
- Feb13Indivior PLCQ4 2024 Earnings Release
- Apr24Indivior PLCQ1 2025 Earnings Release
- Jul24Indivior PLCQ2 2025 Earnings Release
Beschreibung
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.